Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial.
What's New
Ileocaecal resection was associated with nearly three times the rate of 10-year therapy-free remission compared to infliximab in ileocaecal Crohn's disease.
Detailed Summary
A retrospective 10-year follow-up of the LIR!C randomized trial (n=129) found that therapy-free remission was 35.8% after ileocaecal resection versus 13.2% with infliximab (p=0.0038). Overall clinical remission rates were similar between groups, but exploratory analyses suggested younger patients (e.g., age 20) had a larger estimated benefit from resection.
Study Population
Adults with non-stricturing, immunomodulator-refractory ileocaecal Crohn's disease; median age 28 years; 66% female (n=129)
This research is for informational purposes only — discuss with your doctor before making any changes to your care.
Rivvet may earn a referral fee if you book through this link.
Discussion
Loading comments...
Comments are public. Be respectful and remember: this is not medical advice. Do not share personal health information.